A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Inclusion Criteria: * Subject has signed informed consent; * Current DSM-IV-TR diagnosis of schizophrenia; * Clinically stable on the same single second-generation antipsychotic for the past 8 weeks; * Meets study-specific PANSS criteria; * Willing and able to cooperate with cognitive testing * Females are not pregnant, not breast-feeding; * Females are post-menopausal or surgically sterile or practicing birth control; * Males are surgically sterile or agree to be sexually inactive or use barrier method of birth control Exclusion Criteria: * Subject has a substance dependence disorder that has not been in sustained remission for at least 1 year; * Diagnosis of schizoaffective disorder; * Bipolar disorder, manic episode, dementia, OCD, or drug-induced psychosis or current major depressive disorder; * Diagnoses with mental retardation; acute psychosis hospitalization within past 6 months; * Current clozapine treatment; suicidal ideation or behavior; * BMI of 39 or greater; current homicidal or violent ideation; * Medical or CNS condition other than schizophrenia that could affect cognitive performance or testing; relevant drug sensitivity or allergy; positive urine screen for alcohol or drugs of abuse; * Positive hepatitis or HIV test result; * Recent clinically significant illness/infection or surgery; * Recent blood product transfusion, donation or loss of 5 mL/kg of blood; * Visual, hearing or communication disability